Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Janux Therapeutics’ $296.5 Million Common Stock Offering
Keywords Studios’ £76.5 Million Acquisition of The Multiplayer Group From Improbable Worlds Ltd
Macfarlanes advised Improbable Worlds Limited while DWF acted for Keywords Studios on the deal. Keywords Studios, the international provider of creative and technology-enabled solutions to the...
PMG’s Acquisition of RocketMill
Macfarlanes advised PMG on its acquisition of RocketMill. PMG has acquired UK-based RocketMill, a leading independent, full-service digital marketing agency. The combined strengths of PMG and...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
CytomX’s Research Collaboration With Moderna
Latham & Watkins LLP advised CytomX in the transaction. CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna,...
Distributed Solar Development’s Groundbreaking US$155 Million Securitization
Sidley represented Distributed Solar Development, LLC on the deal. Distributed Solar Development, LLC (“DSD”), a leader in large-scale, custom solar PV and energy storage solutions, announced a...
CytomX’s Collaboration and Licensing Agreement With Regeneron Pharmaceuticals
Latham & Watkins LLP represented CytomX in the transaction. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX) have announced a collaboration and licensing...
Orbital Therapeutics’ Partnership With Beam Therapeutics
Latham & Watkins advised Orbital Therapeutics on the deal. Orbital Therapeutics, which aims to enhance global health by unleashing the full potential of RNA medicine, announced...
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
Universities Superannuation Scheme’s £300 Million Acquisition of the Real Estate Assets of Butlin’s
Gowling WLG advised private pension fund provider Universities Superannuation Scheme. The pension fund acquired the underlying real estate interest of the holiday resort operator’s sites at...
HilleVax’s $200 Million Initial Public Offering
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
Twist Bioscience’s $250 Million Common Stock Offering
Orrick, Herrington & Sutcliffe advised Twist Bioscience, while Latham & Watkins represented the underwriters in the offering. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers...